Olaparib

Manufactured by Bio-Connect

Olaparib is a laboratory reagent that functions as a poly(ADP-ribose) polymerase (PARP) inhibitor. It is used in research applications to study PARP-related cellular processes.

Automatically generated - may contain errors

Lab products found in correlation

Hydroxyurea, by Merck Group (1 mentions) Prism 10, by GraphPad (1 mentions) Sorafenib, by Enzo Life Sciences (1 mentions) Milli q gradient water purification system, by Merck Group (1 mentions) Formic acid, by Merck Group (1 mentions)

3 protocols using olaparib

RPE1 cells survival assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

RPE1 cells lines were seeded at 3000 cells/well in 6-well plates and allowed to attach overnight. TULIP2 constructs were induced with 1 µg/mL doxycycline prior treatment. Olaparib (Bio-connect) was added at different concentrations for 24 h. After treatment, medium was refreshed. Hydroxyurea (Sigma) was added at different concentrations and medium was refreshed after 16 h treatment. Subsequently, cells were allowed to grow for 10 days and fixed for 20 min in 4% paraformaldehyde (PFA) in PBS. Cells were stained with Crystal Violet 0.05% for 30 min and washed with water. Afterward, Crystal Violet was re-solubilized in methanol and O.D.595 was measured in the VICTOR X3 Multilabel Plate Reader 2030-0030 (Perkin Elmer). GraphPad Prism 10 was used for statistical analysis and the value of untreated cells was set at 100% survival.

Salas-Lloret D., García-Rodríguez N., Soto-Hidalgo E., González-Vinceiro L., Espejo-Serrano C., Giebel L., Mateos-Martín M.L., de Ru A.H., van Veelen P.A., Huertas P., Vertegaal A.C, & González-Prieto R. (2024). BRCA1/BARD1 ubiquitinates PCNA in unperturbed conditions to promote continuous DNA synthesis. Nature Communications, 15, 4292.

+ Open protocol

+ Expand

Solvent-Mediated Drug Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols

All drugs were solubilized in 10% DMSO. All drugs were purchased from Sigma except for olaparib (Bioconnect) and sorafenib (Enzo Lifesciences).

Galle E., Thienpont B., Cappuyns S., Venken T., Busschaert P., Van Haele M., Van Cutsem E., Roskams T., van Pelt J., Verslype C., Dekervel J, & Lambrechts D. (2020). DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer. Clinical Epigenetics, 12, 27.

+ Open protocol

+ Expand

Quantification of Anticancer Drugs in EDTA Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Regorafenib (RGF), regorafenib M2 (RGF M2), olaparib (OPR), vemurafenib (VMF), cobimetinib (CBT), niraparib (NPR), cabozantinib (CBZ) and dabrafenib (DBF) were obtained from Bio‐Connect BV (Huissen, The Netherlands). The isotopes ¹³C²H₃‐regorafenib, ²H₈‐olaparib, ¹³C₆‐vemurafenib, ¹³C₆‐cobimetinib, ¹³C₆‐niraparib, ²H₄‐cabozantinib and ²H₉‐dabarefenib used as internal standards, were acquired from Alsachim (Illkirch, France). Dimethyl‐sulfoxide (DMSO, Seccosolv) and acetonitrile (ACN, Lichrosolv) were purchased from Merck (Darmstadt, Germany). Formic acid was obtained from Sigma‐Aldrich (Zwijndrecht, The Netherlands). High‐purity Milli‐Q water was produced using a MilliQ Gradient water purification system (Millipore, Amsterdam, The Netherlands). Ethylenediaminetetraacetic acid (EDTA) plasma was prepared from EDTA whole blood obtained from Sanquin (Amsterdam, The Netherlands).

Krens S.D., van der Meulen E., Jansman F.G., Burger D.M, & van Erp N.P. (2020). Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS. Biomedical Chromatography, 34(3), e4758.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!